|
Market Closed -
Hong Kong S.E.
12:08:03 26/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 9.525 HKD | +1.22% |
|
+9.67% | +12.99% |
| 08-26 | CSPC Pharma's Colorectal Cancer Drug Candidate Gets Fast Track Designation by US FDA | MT |
| 08-26 | CSPC Pharma's Lung Cancer Candidate Meets Progression-Free Survival Primary Endpoint | MT |
Company Valuation: CSPC Pharmaceutical Group Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 100,932 | 97,707 | 86,022 | 55,169 | 96,380 | 108,900 | - | - |
| Change | - | -3.19% | -11.96% | -35.87% | 74.7% | 12.99% | - | - |
| Enterprise Value (EV) 1 | 89,633 | 86,241 | 72,284 | 46,931 | 86,710 | 98,084 | 94,840 | 91,423 |
| Change | - | -3.79% | -16.18% | -35.07% | 84.76% | 13.12% | -3.31% | -3.6% |
| P/E | 14.7x | 14.1x | 13.5x | 12.1x | 21.8x | 10.8x | 16x | 14.8x |
| PBR | 3.17x | 2.86x | 2.39x | 1.62x | 2.56x | 2.42x | 2.28x | 2.1x |
| PEG | - | 14.13x | -1.73x | -0.5x | -9.88x | 0x | -0.5x | 1.94x |
| Capitalization / Revenue | 2.94x | 2.77x | 2.52x | 1.78x | 3.26x | 2.82x | 3.06x | 2.87x |
| EV / Revenue | 2.61x | 2.44x | 2.12x | 1.51x | 2.94x | 2.54x | 2.66x | 2.41x |
| EV / EBITDA | 9.5x | 9.43x | 8.39x | 6.22x | 12.1x | 7.09x | 10x | 8.6x |
| EV / EBIT | 10.7x | 10.8x | 9.77x | 7.68x | 15.6x | 8.08x | 12x | 10.9x |
| EV / FCF | 23.7x | 14.1x | 26.2x | 17.5x | 19.5x | 12.5x | 14.6x | 13.6x |
| FCF Yield | 4.22% | 7.11% | 3.82% | 5.71% | 5.12% | 8.03% | 6.83% | 7.36% |
| Dividend per Share 2 | 0.18 | 0.21 | 0.28 | 0.26 | 0.29 | 0.4517 | 0.3622 | 0.386 |
| Rate of return | 2.13% | 2.56% | 3.86% | 5.44% | 3.44% | 4.74% | 3.8% | 4.05% |
| EPS 2 | 0.5773 | 0.5831 | 0.5376 | 0.3946 | 0.3859 | 0.8859 | 0.5972 | 0.6428 |
| Distribution rate | 31.2% | 36% | 52.1% | 65.9% | 75.2% | 51% | 60.7% | 60.1% |
| Net sales 1 | 34,309 | 35,292 | 34,175 | 31,046 | 29,533 | 38,624 | 35,629 | 37,936 |
| EBITDA 1 | 9,431 | 9,148 | 8,615 | 7,547 | 7,168 | 13,833 | 9,450 | 10,627 |
| EBIT 1 | 8,366 | 7,952 | 7,400 | 6,113 | 5,564 | 12,132 | 7,903 | 8,385 |
| Net income 1 | 6,901 | 6,949 | 6,382 | 4,632 | 4,409 | 10,121 | 6,982 | 7,527 |
| Net Debt 1 | -11,298 | -11,467 | -13,738 | -8,238 | -9,670 | -10,815 | -14,060 | -17,476 |
| Reference price 2 | 8.470 | 8.200 | 7.260 | 4.780 | 8.430 | 9.525 | 9.525 | 9.525 |
| Nbr of stocks (in thousands) | 11,916,370 | 11,915,520 | 11,848,756 | 11,541,665 | 11,433,025 | 11,433,025 | - | - |
| Announcement Date | 22/03/22 | 22/03/23 | 20/03/24 | 28/03/25 | 25/03/26 | - | - | - |
1HKD in Million2HKD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 10.62x | 2.51x | 7x | 4.8% | 13.73B | |
| 35.12x | 12.73x | 25.81x | 0.56% | 1,100B | |
| 30.38x | - | - | 1.97% | 658B | |
| 33.92x | 7.84x | 16.3x | 2.58% | 470B | |
| 20.83x | 4.94x | 12.23x | 2.67% | 372B | |
| 22.71x | 5.84x | 14.47x | 2.73% | 304B | |
| 21.88x | 4.48x | 12.79x | 1.96% | 264B | |
| 27.97x | 7.21x | 12.8x | 2.28% | 239B | |
| 13.99x | 4.96x | 10.35x | 3.67% | 213B | |
| -45.46x | 6.56x | 25.6x | 2.22% | 184B | |
| Average | 17.20x | 6.34x | 15.26x | 2.54% | 381.66B | |
| Weighted average by Cap. | 25.25x | 8.39x | 18.50x | 1.9% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 1093 Stock
- Valuation CSPC Pharmaceutical Group Limited
Select your edition
All financial news and data tailored to specific country editions
